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1  | INTRODUC TION
Chlamydia trachomatis infection is the most prevalent bacterial sex‐
ually transmitted disease with over 130 million cases detected an‐
nually worldwide.1 Up to 80% of infections are asymptomatic and 
may therefore remain undiagnosed. If the infection is not resolved, 
C trachomatis can ascend to the upper genital tract and cause pelvic 
inflammatory disease (PID) which increases the risk of tubal factor 
infertility (TFI).2
Laparoscopy has remained the gold standard for the diagnosis of 
TFI. However, it is costly, invasive and can potentially cause complica‐
tions. Hysterosalpingography (HSG) and hysterosalpingosonography 
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Problem: The accuracy of Chlamydia trachomatis antibody test in predicting tubal fac‐
tor infertility (TFI) is limited, and more accurate methods are needed. Cell‐mediated 
immune response (CMI) is crucial in the resolution of pathogen, but it may play an 
important role in the pathogenesis of C trachomatis‐associated tubal damage. We 
studied whether combining the markers of C trachomatis‐induced CMI to humoral 
immune response improves the accuracy of serology in TFI prediction.
Method of study: Our prospective study consists of 258 subfertile women, of whom 
22 (8.5%) had TFI. Women with other causes for subfertility served as a reference 
group. Serum C trachomatis major outer membrane protein (MOMP) and chlamydial 
heat‐shock	protein	60	(cHSP60)	IgG	antibodies	were	measured	by	ELISA.	CMI	was	
studied by lymphocyte proliferation assay in vitro.
Results: Serological markers were more prevalent in women with TFI than in other 
subfertile	women	(40.9%	vs	12.3%	for	MOMP	IgG	and	27.3%	vs	10.2%	for	cHSP60	
IgG). The best test combination for TFI was C. trachomatis MOMP and cHSP60 anti‐
body	 with	 an	 accuracy	 of	 90.3%,	 sensitivity	 of	 22.7%	 and	 specificity	 of	 96.6%.	
Positive	post‐test	probability	of	this	combination	was	54.2%,	and	negative	post‐test	
probability	was	12.4%.	Adding	of	the	markers	of	CMI	did	not	significantly	improve	
the accuracy of serology in TFI prediction.
Conclusion: The accuracy of TFI prediction increases when the combination of C 
trachomatis MOMP and cHSP60 antibody tests is used. C trachomatis‐induced 
CMI was common in our study population, but the markers of CMI did not predict 
TFI.
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(HSSG) are less risky procedures for TFI diagnosis, but false‐positive 
results are common.3,4 HSG and HSSG are also highly observer‐de‐
pendent, and peritubal adhesions are not visualized by these pro‐
cedures. In addition, these methods do not reveal impaired tubal 
function. In a recent meta‐analysis, the sensitivity and specific‐
ity	were	95%	 (78%‐99%)	 and	93%	 (89%‐96%)	 for	HSSG,	 and	94%	
(74%‐99%)	and	92%	(87%‐95%)	for	HSG	compared	to	laparoscopy.3
Numerous studies have shown that positive C. trachomatis se‐
rology is associated with tubal damage.5,6 Therefore, C. trachomatis 
IgG	antibody	 testing	 (CAT)	has	been	used	 in	 infertility	work‐up	 to	
screen subfertile women with the highest risk of tubal pathology.7,8 
However, the accuracy of these tests is limited. The main limitations 
are the high rate of false‐positive results and low positive predictive 
value (PPV).9,10 More accurate, non‐invasive methods are needed for 
TFI diagnostics.
In chronic C. trachomatis infection, the expression of chlamyd‐
ial heat‐shock protein 60 (cHSP60) is highly upregulated. Several 
studies have shown that immune responses to cHSP60 are asso‐
ciated with PID, tubal occlusion and ectopic pregnancy (EP).11,12 
Furthermore, the presence of serum antibodies against cHSP60 may 
also predict TFI.13,14
The clearance of C. trachomatis is known to depend on cell‐medi‐
ated immune response (CMI).15 However, in addition to the protec‐
tive function, CMI is also associated with inflammatory pathological 
processes resulting in tubal damage.16‐18 The role of CMI in predict‐
ing TFI has been examined in our earlier studies, in which in vitro 
lymphocyte response against C trachomatis was more often detected 
in women with TFI than in healthy controls.14,18	As	a	result,	we	hy‐
pothesized that TFI prediction model could be further improved by 
adding markers of CMI to serology.
The aim of our study was to evaluate if combining markers of 
cell‐mediated and humoral immune response against C. trachomatis 
improves the accuracy of serology in the prediction of TFI in clinical 
practice.
2  | MATERIAL S AND METHODS
2.1 | Study population
Our study population consisted of 258 subfertile women referred 
for infertility investigations to Helsinki University Hospital during 
July	2007	‐	December	2010.	Infertility	work‐up	was	performed	ac‐
cording to our routine protocol after at least one year of unprotected 
intercourse. The first visit in the fertility clinic included gynaeco‐
logical examination and ultrasonography of uterus and adnexa. 
Ovulatory menstrual cycle was monitored by the growth of the fol‐
licle in ultrasound and by measuring serum mid‐luteal progesterone. 
Hormonal disorders were diagnosed by determination of serum gon‐
adotropins and progesterone and by analysing serum prolactin and 
thyroid function tests. First‐void urine or a cervical swab specimen 
was collected for the diagnosis of C. trachomatis by the nucleic acid 
amplification	test	(NAAT).	Semen	samples	of	the	male	partners	were	
analysed according to the criteria of the World Health Organization 
(WHO).
Tubal patency was evaluated either by HSSG or by diagnostic 
laparoscopic tubal evaluation. TFI was defined as a visible occlusion 
of at least one tube. HSSG was performed by a fertility specialist by 
instilling	0.9%	 saline	 and	air	 into	uterus	 and	 following	 the	path	of	
air bubbles through the fallopian tubes. Tubal status in HSSG was 
classified as no occlusion, unilateral occlusion or bilateral occlusion. 
Bilateral tubal occlusion or unclear result in HSSG was confirmed by 
laparoscopy. Laparoscopy was performed also in a suspicion of deep 
rectovaginal endometriosis, in the presence of large endometrioma 
requiring operational treatment or if severe symptoms consistent 
with endometriosis were present. Laparoscopic tubal evaluation 
was performed by chromopertubation, where methylene blue was 
injected through a catheter into the uterine cavity and the passage 
of dye was followed through the fallopian tubes. Laparoscopic cri‐
terium for endometriosis was a direct visualization of ectopic en‐
dometrial lesions, usually accompanied by pelvic adhesions. Cases 
with EP before or during infertility evaluation (n = 11) were in‐
cluded in the unilateral TFI group. Subfertile women with another 
aetiology	for	subfertility,	such	as	ovulatory	disorder	(n	=	69),	endo‐
metriosis	(n	=	37),	male	factor	infertility	(n	=	25),	unexplained	infer‐
tility	(n	=	96)	or	other	sporadic	cause	(hormonal	disorder,	structural	
anomaly	or	pelvic	adhesions	due	to	previous	pelvic	surgery;	n	=	9),	
served as the reference group.
Participants were followed to the first delivery or until June 
2014.	Clinical	data	on	the	results	of	 infertility	examinations,	 treat‐
ment and subsequent pregnancy were collected from the patient 
register of Helsinki University Hospital.
2.2 | Serological analysis and lymphocyte 
proliferation assay
Blood samples for immunological analysis were collected at the first 
visit and analysed at the National Institute for Health and Welfare 
in Oulu, Finland. Both humoral and cell‐mediated immune responses 
to C. trachomatis were studied. C. trachomatis MOMP‐specific and 
cHSP60‐specific IgG antibodies were analysed by commercially avail‐
able	ELISA	kits	 (Medac	Diagnostika,	Hamburg,	Germany)	according	
to manufacturer’s instructions. This peptide‐based C. trachomatis 
MOMP	ELISA	 is	 considered	species‐specific	with	minimal	cross‐re‐
activity to other Chlamydia species.9 Results were obtained as a mean 
absorbance	of	duplicated	samples	at	450	nm.	Less	than	10%	variation	
was seen in doublets (OD > 0.2). Cut‐off for a positive antibody level 
(mean	OD	value	of	the	negative	control	+0.350)	was	OD	>	0.4.
Chlamydia trachomatis‐specific CMI was analysed in vitro by 
lymphocyte proliferation test. Viable cells for the analysis were 
available	 from	 234	 patients.	 C. trachomatis elementary body (EB; 
serovar E and F, total protein concentration 3 µg/mL) and recom‐
binant CHSP60 (2.5 µg/mL) were used as lymphocyte‐stimulating 
antigens.15 The results were expressed as stimulation indices (SI, or 
mean count per minute in the presence of antigen, divided by mean 
count per minute in its absence) for triplicate cultures. SI > 5 was 
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considered a positive response to chlamydial EB antigen, and SI > 2.5 
was considered a positive response to cHSP60 antigen.
2.3 | Statistical analysis
Chi‐squared test was used for the analysis of categorical data. 
Continuous variables were compared by Student’s t test or Mann–
Whitney U‐test as appropriate. To evaluate the prognostic value of 
immunological tests for tubal pathology, we calculated sensitivity, 
specificity, PPV, negative predictive value (NPV), positive likelihood 
ratio (LR+) and negative likelihood ratio (LR–). Post‐test probabil‐
ity was calculated as (pre‐test odds*likelihood ratio)/(1 + pre‐test 
odds*likelihood ratio), where pre‐test odds = pre‐test probability/
(1–pre‐test probability). Estimated TFI prevalence of 15% was used 
when calculating post‐test probability. The diagnostic performance 
of the tests was analysed by receiver operating characteristic (ROC) 
curves. Statistical analyses were performed with IBM SPSS Statistics 
22.0	(IBM	Corp.,	Armonk,	NY,	USA).
3  | RESULTS
3.1 | TFI in the study population
TFI was observed in 22 (8.5%) of the 258 women. The patency of 
fallopian	tubes	was	evaluated	by	laparoscopy	in	51	(19.8%)	and	by	
HSSG in 160 (62.0%) women. Both procedures were performed for 
eight (3.1%) women. Tubal patency was not evaluated in women who 
conceived	 spontaneously	before	 tubal	 evaluation	 (n	=	24)	or	were	
admitted directly to IVF (n = 23). Of all the 22 TFI cases, bilateral 
tubal	occlusion	was	found	in	five	cases,	and	17	women	had	unilat‐
eral	tubal	occlusion.	Altogether,	11	women	included	in	the	TFI	group	
had EP before or during infertility work‐up. Of the 11 women with 
EP, five had tubal occlusion and five had patent tubes. One of the 11 
women with EP conceived spontaneously before tubal evaluation, 
but the pregnancy resulted in EP and was treated by salpingectomy. 
The flow chart of the study population is presented in Figure 1.
The baseline characteristics of the study population are shown 
in Table 1. Women with TFI were older than women with other 
causes of subfertility (mean 33.1 vs 31.2 years, P =	0.04)	and	were	
more	likely	to	have	secondary	infertility	(54.5%	vs	27.1%,	P =	0.007).	
Smoking was associated with TFI (38.1% vs 16.0%, P = 0.03). 
Altogether,	37	(14.3%)	of	the	258	women	reported	prior	history	of	
chlamydial infection and six (2.3%) reported recurrent (two or more 
episodes) infection. Three women (1.2%) reported a history of PID. 
None of the participants had a positive C. trachomatis NAAT	from	
urogenital sample at the time of infertility evaluation. During the 
follow‐up, the live birth rate was significantly lower in the TFI group 
than	in	the	non‐TFI	group	(58.8%	vs	89.8%,	P < 0.001).
3.2 | Immune response to C. trachomatis
The prevalence of C. trachomatis‐induced humoral and cell‐medi‐
ated immunological markers in the study population is shown in 
Table	 2.	 All	 serological	markers	were	more	 often	 positive	 in	 TFI	
cases than in cases with other causes for subfertility. Table 3 
shows the performance of immunological tests and test combina‐
tions. C. trachomatis MOMP antibody test was the best single test 
(area	 under	ROC	 curve	0.73;	 95%	CI	 0.61‐0.85)	 in	 the	 detection	
of	TFI,	with	an	accuracy	of	83.7%,	sensitivity	of	40.9%	and	speci‐
ficity	of	87.7%.	PPV	of	 the	MOMP	antibody	 test	 (in	our	popula‐
tion	with	8.5%	TFI	rate)	was	23.7%	and	NPV	was	94.1%	(Figure	2,	
F I G U R E  1   Flow chart of the study population. aTen women 
were excluded for the following reasons: not meeting the criteria 
for infertility investigation (n = 5), not willing to have infertility 
investigation (n = 2) or referred directly to IVF from another 
clinic (n = 3). bOne of the 11 women with ectopic pregnancy 
(EP) conceived spontaneously before tubal evaluation, but the 
pregnancy resulted in EP and was treated by salpingectomy
Tubal status examined n = 211: 
• HSSG (n = 160)
• Laparoscopy (n = 51)
• HSSG and laparoscopy 
(n = 8)
Subferle women included in the 
cohort n = 258
Subferle women recruited 
N = 268
Tubal pathology n = 35:
• Tubal occlusion (n = 24)
• Ectopic pregnancy (n = 11)
Tubal factor inferlity n = 22b
• HSSG (n = 8)
• Laparoscopy (n = 10)
• HSSG and laparoscopy (n = 3)
Excluded n = 10a
Tubal status not 
examined n = 47
Tubal occlusion caused 
by endometriosis or 
previous pelvic surgery 
n = 13
TA B L E  1   Baseline characteristics of the study population
TFI (n = 22) Non‐TFI (n = 236) P‐value
Age	in	years	
(mean [SD])
33.1	(4.9) 31.2	(4.0) 0.04
Secondary 
infertility (n, %)
12	(54.5) 64	(27.1) 0.007
Past genital 
chlamydia 
infectiona (n, %)
4	(18.2) 33	(14.2) 0.54
Smokingb (n, %) 8 (38.1) 37	(16.0) 0.03
Body mass indexc 
(median [range])
22.5 (18‐35) 23	(17‐41) 0.65
aSelf‐reported	infection,	no	data	in	4	cases.	
bNo data in 6 cases. 
cNo data in 2 cases. 
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Table 3). PPV increased to 38.5% when the combination of MOMP 
and cHSP60 antibody was used. When combining MOMP antibody 
and	EB	lymphocyte	proliferation	test,	the	PPV	was	27.6%	and	NPV	
was	 93.7%.	When	 the	 combination	 of	MOMP	 antibody,	 cHSP60	
antibody and EB lymphocyte proliferation test was used, the 
PPV	increased	to	40.0%	(Table	3).	Positive	and	negative	post‐test	
probabilities are shown in Table 3. Positive post‐test probability 
of	 the	 combination	of	MOMP	and	 cHSP60	 antibody	was	54.2%,	
and	54.4%	when	EB	proliferation	test	was	combined	with	the	sero‐
logical combination. LR+and LR– of MOMP and cHSP60 antibody 
combination	were	6.7	and	0.8,	respectively.	Adding	cHSP60	lym‐
phocyte proliferation test to serological tests did not increase the 
performance of the tests.
4  | DISCUSSION
The aim of our study was to evaluate whether C. trachomatis serol‐
ogy for TFI prediction can be improved by combining tests of C. tra‐
chomatis‐specific humoral and cell‐mediated immune response. We 
found that the accuracy of TFI prediction increases when the combi‐
nation of C. trachomatis MOMP and cHSP60 antibody tests is used. 
Adding	the	markers	of	CMI	to	the	antibody	tests	did	not	significantly	
improve the accuracy of TFI prediction.
Of the single tests, cHSP60 IgG had the highest specificity for 
predicting TFI in our study, but the sensitivity of the test was low 
indicating a high number of cHSP60‐negative cases among women 
with TFI C. trachomatis MOMP IgG test yielded better sensitivity, 
but as shown in previous studies ,6,10 it had relatively low specificity 
TA B L E  2   The prevalence (%) of positive immunological tests 
against Chlamydia trachomatis and cHSP60 in TFI cases and in 
women with other causes for subfertility
TFI (N = 22) Non‐TFI (N = 236) P‐value
Humoral immune markers (%, n)
C. trachomatis 
MOMP IgG
40.9	(9/22) 12.3	(29/236) 0.002
cHSP60 IgG 27.3	(6/22) 10.2	(24/236) 0.03
Cell‐mediated immune markersa (%, n)
C. trachomatis 
EB LP 
response
85.7	(18/21) 67.1	(143/213) 0.08
cHSP60 LP 
response
23.8 (5/21) 28.6 (61/213) 0.64
Combination of immune markersa (%, n)
C. trachomatis 
MOMP IgG 
and cHSP60 
IgG
22.7	(5/22) 3.4	(8/236) 0.002
C. trachomatis 
MOMP IgG 
and EB LP 
response
38.1 (8/21) 9.1	(21/213) <0.001
C. trachomatis 
MOMP IgG 
and cHSP60 
IgG and EB 
LP response
19.0	(4/21) 2.8 (6/213) 0.007
EB, C. trachomatis elementary body; LP, lymphocyte proliferation.
aData	on	CMI	response	missing	in	24	cases.	
TA B L E  3   Predictive value of the single and combination tests for predicting TFI
Sensitivity 
(%)
Specificity 
(%)
Accuracy 
(%)
PPV 
(%) NPV (%) LR+ LR–
Positive post‐test 
probability (%)
Negative 
post‐test 
probability 
(%)
Humoral immune response
C. trachomatis MOMP 
IgG
40.9 87.7 83.7 23.7 94.1 3.3 0.7 37.0 10.6
cHSP60 IgG 27.3 89.8 84.5 20.0 93.0 2.7 0.8 32.1 12.5
Cell‐mediated immune response
C. trachomatis EB LP 
response
85.7 32.9 37.6 11.2 95.9 1.3 0.4 18.4 7.1
cHSP60 LP response 23.8 71.4 67.1 7.6 90.5 0.8 1.1 12.8 15.9
Combinations of immune markers
C. trachomatis MOMP 
IgG and cHSP60 IgG
22.7 96.6 90.3 38.5 93.0 6.7 0.8 54.2 12.5
C. trachomatis MOMP 
IgG and EB LP 
response
38.1 90.1 85.5 27.6 93.7 3.9 0.7 40.5 10.8
C. trachomatis MOMP 
IgG and cHSP60 IgG 
and EB LP response
19.0 97.2 90.2 40.0 92.4 6.8 0.8 54.4 12.8
Post‐test probability was calculated with pre‐test probability value 15% for TFI.
EB, elementary body; LP, lymphocyte proliferation.
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in predicting TFI although this is a species‐specific test for detect‐
ing serum C trachomatis antibodies.9 This is likely to result from a 
high number of sero‐positive cases among women with non‐TFI 
subfertility.
We found that the specificity of C trachomatis serology can be 
improved by using the combination of MOMP and cHSP60 antibody. 
This	combination	had	highest	accuracy	 (90.3%)	and	PPV	of	38.5%	
in our study population in which TFI prevalence was 8.5%. While 
PPV depends on the prevalence of the disease, the predictive value 
of the test combination would be higher in a population with higher 
TFI prevalence. With an estimated pre‐test TFI prevalence of 15%, 
this	antibody	combination	indicates	a	54.2%	risk	of	C trachomatis‐in‐
duced TFI after a positive test result.
When evaluating the performance of a clinical test, LR is con‐
sidered more useful measure than sensitivity and specificity.19,20 LR 
summarizes how many times more (or less) likely patient with the dis‐
ease is to have positive test result than patient without the disease. 
LR+ of the combination of C trachomatis MOMP IgG and cHSP60 IgG 
was	6.7,	suggesting	that	this	test	combination	is	moderately	useful	
in clinical practice to “rule in” women with TFI. However, the LR– of 
this combination was 0.8, which suggests a high number of false‐
negative cases who may have had tubal occlusion not related to C 
trachomatis, or who had not developed detectable immunological 
response to MOMP and cHSP60. Because false‐negative test result 
may lead to ineffective treatment, we consider that high sensitivity 
and low LR– are more important than high specificity and high LR+ 
for TFI screening in clinical practice.
The sensitivity of cHSP60 antibody or cHSP60 lymphocyte pro‐
liferation test was low in our study, consistent with a high number 
of cHSP60‐negative cases among women with TFI. The overall 
prevalence of cHSP60 antibodies and positive cHSP60 lymphocyte 
proliferation test was lower than expected. Immune response to 
cHSP60 has been linked to chronic or repeat chlamydial infection,17 
but our results suggest that cHSP60 test may be poorer marker of 
C. trachomatis‐related sequelae than previously assumed.12,21 Due 
to opportunistic C. trachomatis screening, chronic infections may 
have become less common. It is also possible that the virulence of 
C. trachomatis has changed over time, so that current serovars are 
less likely to ascend to the upper genital tract.22 The relatively low 
prevalence of TFI (8.5%) in our study supports this hypothesis.
The course of a single C. trachomatis infection varies individu‐
ally. The majority of women who have serological evidence of past 
exposure to C. trachomatis have cleared the infection without any 
reproductive consequences, whereas others have persistent infec‐
tion increasing the risk of TFI. The individual factors influencing the 
pathogenic mechanisms of TFI are strongly related to the environ‐
ment and host variables.23 Furthermore, tubal damage can vary from 
visible intra‐tubal adhesions to milder forms without tubal occlusion. 
In our study, tubal evaluation was mainly performed by HSSG which 
is known to have limited accuracy and low inter‐observer reproduc‐
ibility.3 Moreover, peritubal adhesions or minor tubal damage (ie, 
destruction of functional tubal epithelium and loss of cilia) cannot 
be revealed by this procedure. These milder forms of TFI may lead 
to impaired function of fimbriae or fallopian tubes. In our study, 
women with EP were included in the TFI group, since EP suggests 
tubal disease.
Chlamydia trachomatis‐associated proportion of all TFI is esti‐
mated	to	be	between	29%	to	45%,	and	repeat	episodes	of	chlamydial	
F I G U R E  2  Areas	under	receiver	
operating characteristic ‐curves in the 
prediction of TFI by C. trachomatis‐
specific and cHSP60‐specific immune 
markers. The best single test for TFI 
prediction was C. trachomatis MOMP 
IgG	(area	under	ROC	curve	0.73;	95%	CI	
0.61‐0.85). EB, elementary body; LPR, 
lymphocyte proliferation response
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infection increase the risk of tubal damage.24 However, the patho‐
genesis of TFI is multifactorial. Not all TFI is attributed to prior 
C. trachomatis infection which reduces the performance of C. tracho‐
matis‐specific immunological tests in the prediction of TFI.
Our finding of lower live birth rate in TFI patients than in pa‐
tients with other causes of subfertility is consistent with previ‐
ous studies.25,26 It is well established that women with untreated 
hydrosalpinges are at higher risk of implantation failure and mis‐
carriage.27,28 In our study population, two women had untreated 
hydrosalpinges. It is also possible that women with post‐infectious 
TFI have chronic endometrial inflammation resulting in impaired 
implantation.29,30
To the best of our knowledge, this is the first study evaluating 
the combinations of C trachomatis‐induced humoral and cell‐medi‐
ated immune responses in predicting TFI in clinical setting. C tracho‐
matis‐specific immune responses in the TFI cases were comparable 
to those in our earlier studies.14,18 However, the study design and 
the study population were different. In the present study, immune 
responses against C. trachomatis were measured in an unselected 
subfertile population, whereas in previous studies immune re‐
sponses were compared between TFI cases and healthy controls. 
Furthermore, the TFI cases in the previous studies had more se‐
vere forms of tubal damage, while in this study population only five 
women had bilateral tubal damage. In our study population, C. tra‐
chomatis‐specific immune responses were common also in women 
with other causes for subfertility than TFI.
5  | CONCLUSIONS
In conclusion, the value of serology in evaluating C. trachomatis‐as‐
sociated TFI can be improved by combining serum C. trachomatis 
MOMP and cHSP60 IgG antibody tests, or combining EB lympho‐
cyte proliferation test to C. trachomatis serology. However, C. tra‐
chomatis immune markers in the prediction of TFI are only of modest 
value due to the multifactorial nature of TFI development. Further 
studies are needed to elucidate the mechanisms of C. trachomatis as‐
cension to the upper genital tract and its exact role in chronic inflam‐
mation leading to subfertility.
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